SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: A gold-standard for HIV-1 vaccine development?

Current HIV Research

Volumn 7, Issue 5, 2009, Pages 497-503

  Sealy, Robert ^a   Zhan, Xiaoyan ^a,d   Lockey, Timothy D ^a   Martin, Louis ^b   Blanchard, James ^b   Traina Dorge, Vicki ^b   Hurwitz, Julia L ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neutralization; Protective immunity; Rhesus macaques; SHIV; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; NONHUMAN; RETROVIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; SUPERINFECTION; VIRUS LOAD;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 70350714603     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209789346255     Document Type: Article

References (57)

1. Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008; 372: 1857-1858
2. Hurwitz JL, Zhan X, Brown SA, et al. HIV-1 vaccine development: Tackling virus diversity with a multi-envelope cocktail. Frontiers Biosci 2008; 13: 609-620 (Pubitemid 351599771)
3. Zhan X, Martin LN, Slobod KS, et al. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV. Vaccine 2005; 23: 5306-5320 (Pubitemid 41579300)
4. Nyambi PN, Nadas A, Mbah HA, et al. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol 2000; 74: 10670-10680 (Pubitemid 30815388)
5. Johnston MI, Fauci AS. An HIV vaccine - challenges and prospects. N Engl J Med 2008; 359: 888-890
6. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321: 530-532
7. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 2006; 124: 677-681
8. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine 2006; 24: 4062-4081
9. Jefferys R. Pleas for a back-to-basics approach. IAVI Report, The Publication on International AIDS Vaccine Research. January 2008.
10. Berry N, Stebbings R, Ferguson D, et al. Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol 2008; 89: 2240-2251
11. Connor RI, Montefiori DC, Binley JM, et al. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998; 72: 7501-7509
12. Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, et al. Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol 2009; 83: 2686-2696
13. Clements JE, Montelaro RC, Zink MC, et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995; 69: 2737-2744
14. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-1941 (Pubitemid 23026733)
15. Stephens EB, Joag SV, Atkinson B, et al. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV(KU-1). Virology 1997; 234: 328-339 (Pubitemid 27360125)
16. Rasmussen RA, Montefiori DC, Robinson HL, McClure HM, Ruprecht RM. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin. J Infect Dis 2001; 184: 1603-1607
17. Kim EY, Busch M, Abel K, et al. Retroviral recombination in vivo: viral replication patterns and genetic structure of simian immunodeficiency virus (SIV) populations in rhesus macaques after simultaneous or sequential intravaginal inoculation with SIVmac239Deltavpx/Deltavpr and SIVmac239Deltanef. J Virol 2005; 79: 4886-4895
18. Mackay GA, Liu Z, Singh DK, et al. Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus. J Immunol 2004; 173: 4100-4107 (Pubitemid 39280775)
19. Cranage MP, Whatmore AM, Sharpe SA, et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997; 229: 143-154
20. Cranage MP, Sharpe SA, Whatmore AM, et al. In vivo resistance to simian immunodeficiency virus superinfection depends on attenuated virus dose. J Gen Virol 1998; 79 ( Pt 8): 1935-1944
21. Cayabyab M, Karlsson GB, Etemad-Moghadam BA, et al. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simianhuman immunodeficiency virus (SHIV-HXBc2). J Virol 1999; 73: 976-984 (Pubitemid 29036748)
22. Liao HX, Etemad-Moghadam B, Montefiori DC, et al. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. J Virol 2000; 74: 254-263 (Pubitemid 30002905)
23. Reimann KA, Li JT, Voss G, et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996; 70: 3198-3206
24. Reimann KA, Li JT, Veazey R, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996; 70: 6922-6928 (Pubitemid 26307405)
25. Amedee AM, Rychert J, Lacour N, Fresh L, Ratterree M. Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques. Retrovirology 2004; 14: 1-17. (Pubitemid 39130578)
26. Reynolds MR, Weiler AM, Weisgrau KL, et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008; 205: 2537-2550
27. Yankee TM, Sheffer D, Liu Z, et al. Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques. Virology 2009; 383: 103-111
28. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol 2002; 14: 495-502.
29. Van Rompay KK, Berardi CJ, Dillard-Telm S, et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998; 177: 1247-1259 (Pubitemid 28194263)
30. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-206 (Pubitemid 30082366)
31. Foresman L, Jia F, Li Z, et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques. AIDS Res Hum Retroviruses 1998; 14: 1035-1043 (Pubitemid 28371335)
32. Glaudin M-C, Parren PWHI, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3: 1389-1393 (Pubitemid 28011040)
33. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018 (Pubitemid 29189846)
34. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75: 8340-8347
35. Prince AM, Reesink H, Pascual D, et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. Aids Res Hum Retroviruses 1991; 7: 971-973
36. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Postexposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17: 301-309 (Pubitemid 36223254)
37. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994; 7: 211-219 (Pubitemid 2048239)
38. Gottlieb GS, Nickle DC, Jensen MA, et al. Dual HIV-1 infection associated with rapid disease progression. Lancet 2004; 363: 619-622
39. Gerhardt M, Mloka D, Tovanabutra S, et al. In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach. J Virol 2005; 79: 8249-8261 (Pubitemid 40853529)
40. Coetzer M, Cilliers T, Papathanasopoulos M, et al. Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa. Aids Res Hum Retroviruses 2007; 23: 316-321 (Pubitemid 46418346)
41. Casado C, Pernas M, Alvaro T, et al. Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease. J Infect Dis 2007; 196: 895-899 (Pubitemid 47378940)
42. Chakraborty B, Valer L, De MC, Soriano V, Quinones-Mateu ME. Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. Aids Res Hum Retroviruses 2004; 20: 1026-1031 (Pubitemid 39369711)
43. Smith DM, Strain MC, Frost SD, et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006; 355: 1-5.
44. Grobler J, Gray CM, Rademeyer C, et al. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 2004; 190: 1355-1359 (Pubitemid 39287764)
45. Gonzales MJ, Delwart E, Rhee SY, et al. Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 personyears of observation. J Infect Dis 2003; 188: 397-405. (Pubitemid 36960650)
46. Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog 2007; 3: e177. (Pubitemid 350291609)
47. Berman P, Murthy KK, Wrin T, et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996; 173: 52-59 (Pubitemid 26009674)
48. Hu S-L, Abrams K, Barber GN, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255: 456-459
49. Berman PW, Gray AM, Wrin T, et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis 1997; 176: 384-397 (Pubitemid 27328760)
50. Morgan C, Marthas M, Miller C, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008; 5(8): e173.
51. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267: 1820-1825
52. Pal R, Kalyanaraman VS, Nair BC, et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006; 348: 341-353
53. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25: 4085-4092 (Pubitemid 46616987)
54. Hurwitz JL, Lockey TD, Jones B, et al. First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants. AIDS 2008; 22: 149-151 (Pubitemid 350294890)
55. Stambas J, Brown SA, Gutierrez A, et al. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 2005; 23: 2454-2464 (Pubitemid 40340132)
56. Slobod KS, Lockey TD, Howlett N, et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004; 23: 106-110 (Pubitemid 38392137)
57. Sealy R, Slobod KS, Flynn P, et al. Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int Rev Immunol 2009; 28: 49-68.